Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALM: Pazopanib With Low Fat Meal in Advanced Renal Cell Carcinoma
NCT02729194Phase 1Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jun 2016
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pazopanib in renal cell carcinoma (RCC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Number of Grade 3 or 4 Adverse Events, Number of Participants With Dose Reductions at 12 weeks and 2 more. Started Jun 2016; status: completed.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02729194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02729194.